Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 6Phase 3 2Phase 1/2 2Phase 2/3 1

Status

Completed 6Terminated 2Active not recruiting 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 4Mastocytosis, Systemic 2Leukemia, Mast-Cell 2Aggression 2Leukemia 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Completed × midostaurin × Clear all
NCT03280030 2025-03-20

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Novartis

Phase 2 Completed
67 enrolled 21 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01883362 2021-03-17

RADIUS

Novartis

Phase 2 Completed
60 enrolled 17 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01830361 2020-08-06

MIDOKIT

Technische Universität Dresden

Phase 2 Completed
18 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01477606 2020-06-04

Protocol in Acute Myeloid Leukemia With FLT3-ITD

University of Ulm

Phase 2 Completed
451 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Novartis

Phase 2 Completed
116 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT00233454 2018-09-20

Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia

Stanford University

Phase 2 Completed
26 enrolled 12 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡